BB-1705 / BlissBio - LARVOL DELTA

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=288 | Recruiting | Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Trial primary completion date: Dec 2025 ➔ Jun 2025

Trial primary completion date • Oncology • Solid Tumor

Preclinical studies of BB-1705: An EGFR-targeting eribulin-containing ADC with an affinity optimized antibody to minimize potential toxicities to normal tissues (AACR 2025) - "When administered repeatedly via a clinically relevant route and schedule, BB-1705 demonstrated a favorable pharmacokinetic profile and safety in cynomolgus monkeys with manageable hematological side effects and minimal skin toxicity observed even at the highest tested dose (12 mg/kg, Q3W x 3).In summary, our preclinical findings suggest that BB-1705 has the potential to optimize the efficacy and safety profile of EGFR-targeting therapies for cancers characterized by medium to high EGFR expression levels. A clinical trial evaluating BB-1705 is currently underway, aiming to assess its therapeutic potential in treatment of EGFR-expressing human cancers including TNBC, NSCLC and head and neck cancers."

Preclinical • Breast Cancer • Head and Neck Cancer • Liposarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Triple Negative Breast Cancer

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=288 | Recruiting | Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Phase classification: P1/2 ➔ P1 | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Metastases • Phase classification • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Preclinical studies of BB-1705: An EGFR-targeting eribulin-containing ADC with an affinity optimized antibody to minimize potential toxicities to normal tissues (AACR 2023) - "Panitumumab is a fully human monoclonal antibody with extremely high affinity (KD ≈10-11 M) to the epidermal growth factor receptor (EGFR) and could mediate potent blockade to EGFR/EGF engagement. In conclusion, the pharmacological and safety profiles of BB-1705 were well established through in vitro potency testing, in vivo efficacy study and general toxicity studies. This data support BB-1705 as a potent antitumor agent to EGFR medium to high-expressing cancers and warrant further investigation of BB-1705 in human clinic trials."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • EGFR

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=288 | Recruiting | Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

"BB-1705https://www.adcreview.com/drugmap/bb-1705/" (@OncoZine)

Review